Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats

J Steroid Biochem Mol Biol. 2008 Nov;112(1-3):40-6. doi: 10.1016/j.jsbmb.2008.08.008. Epub 2008 Sep 4.

Abstract

Selective estrogen receptor modulators (SERMs) have the potential to treat estrogen sensitive diseases such as uterine leiomyoma and endometriosis, which are prevalent in reproductive age women. However, SERMs also increase the risk of developing ovarian cysts in this population, a phenomenon that is not seen in postmenopausal women. It is believed that current SERMs partially block estradiol's ability to downregulate gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus thereby interfering with estradiol's negative feedback, leading to increased ovarian stimulation by gonadotropins, and cyst formation. It has been postulated that a SERM with poor brain exposure would have less negative effect on the HPO axis, therefore reducing the risk of developing ovarian cysts. In order to test this hypothesis, we identified an early marker of SERM-dependent ovarian effects: upregulation of Cyp17a1 mRNA. SERMs known to cause ovarian cysts upregulate Cyp17a1 after only 4 days of dosing and suppression of the HPO axis prevented this regulation, indicating that ovarian expression of Cyp17a1 was secondary to SERM's effect on the brain. We then characterized three SERMs with similar binding affinity and antagonist effects on the uterus for their relative brain/plasma exposure and ovarian effects. We found that the degree of brain exposure correlated very well with Cyp17a1 expression.

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Brain / metabolism
  • Dose-Response Relationship, Drug
  • Estrogen Receptor alpha / metabolism
  • Female
  • Naphthalenes / administration & dosage
  • Naphthalenes / adverse effects
  • Naphthalenes / pharmacokinetics
  • Ovarian Cysts / metabolism*
  • Ovarian Cysts / pathology
  • Ovary / drug effects
  • Ovary / enzymology*
  • Ovary / pathology
  • Piperidines / administration & dosage
  • Piperidines / adverse effects
  • Piperidines / pharmacokinetics
  • Raloxifene Hydrochloride / administration & dosage
  • Raloxifene Hydrochloride / adverse effects
  • Raloxifene Hydrochloride / pharmacokinetics
  • Rats
  • Rats, Sprague-Dawley
  • Reverse Transcriptase Polymerase Chain Reaction
  • Selective Estrogen Receptor Modulators / administration & dosage
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / pharmacokinetics*
  • Steroid 17-alpha-Hydroxylase / biosynthesis*
  • Up-Regulation

Substances

  • Biomarkers
  • Estrogen Receptor alpha
  • LY2066948
  • Naphthalenes
  • Piperidines
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Steroid 17-alpha-Hydroxylase